NCT02962388终止2 期
A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study
French Innovative Leukemia Organisation1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2017年1月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Failure-free patients
研究概览
简要总结
Prospective national multicenter randomized open label phase IIb RUXBETA trial.
详细描述
A randomized, open label, multicenter phase IIb study to evaluate the efficacy and safety of Ruxolitinib versus best available therapy in patients with high risk essential thrombocythemia, who are resistant or intolerant to hydroxyurea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Target Population
- •Men and women, age more than or equal18 years and less than 75 years.
- •Confirmed diagnosis of Essential Thrombocythemia for at least 6 months, according to the 2008 WHO criteria, with a high-risk status.
- •Patients must have a treatment history for ET that meet the definition of resistance or intolerance to hydroxyurea therapy according to the ELN criteria as follow:
- •Platelets more than 600.0109/L after 3 months (12 weeks) of treatment at a dose over 2g/day.
- •Platelets more than 400.0 109/L and WBC less than 2.5109/L, whatever the dose of HU.
- •Platelets more than 400.0 109/L and Hb less than 10g/dl whatever the dose of HU.
- •Leg ulcers or other unacceptable muco-cutaneous toxicity.
- •HU-related fever.
- •ECOG Performance Status (ECOG PS) less than or equal 2 at screening and at baseline.
- •Adequate Organ Function:
- •Direct bilirubin less than 2.0 times the institutional Upper Limit of Normal (ULN).
- •Hepatic enzymes (AST, ALT) less than or equal 2.5 times the institutional ULN.
- •Adequate renal function at screening as demonstrated by MDRD-eGFR more than 30 mL/min/1.73m
- •Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy during and after the study.
- •A male subject of fathering potential must use an adequate method of contraception to avoid conception during and after the study to minimize the risk of pregnancy.
- •For females and males, these restrictions apply for 24 hours after the last dose of study drug.
- •Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin hCG pregnancy test at Screening.
- •Signed Written Informed Consent.
- •Health insurance coverage.
排除标准
- •Patients with thrombocytosis related to another MPN than ET
- •Patients previously treated with a JAK2 inhibitor, Anagrelide or Interferon-alpha and prior history of therapy other than Hydroxyurea
- •Contraindication to Ruxolitinib, Anagrelide or Interferon-alpha (if no eligible for anagrelide), hypersensitivity to an excipient
- •Medical history and concurrent diseases:
- •Clinically significant cardiac disease (NYHA Class III or IV).
- •Chronic hepatocellular disease.
- •Subjects with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Ruxolitinib
- •Subjects with clinically significant bacterial, fungal, parasitic or viral infection which requires therapy:
- •Subjects with acute bacterial infections requiring antibiotic use should delay screening/enrolment until the course of antibiotic therapy has been completed.
- •Subjects with active hepatitis A, B or C or with HIV positivity at screening.
- •Subjects with diagnosed primary immunodeficiency syndromes such as X-Linked a gammaglobulinemia and common variable immune deficiency.
- •Subject with medical history of tuberculosis
- •History of progressive multifocal leucoencephalopathy (PML).
- •Other malignant disease during the last 5 years prior to the inclusion except treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, with no evidence for recurrence in the past 3 years.
- •History of significant bleeding disorder not related to the ET.
- •Diagnosed congenital bleeding disorders,
- •Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VIII antibodies),
- •Ongoing or recent (3 months) significant gastrointestinal bleeding.
- •Subjects with an uncontrolled undercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol.
- •Subjects being treated concurrently with a potent systemic inhibitor of CYP3A4 at the time of screening.
- •Subjects being treated concurrently with any prohibited medications.
- •Women who are pregnant or breastfeeding are not eligible for this study.
- •Inability to freely provide consent through judiciary or administrative condition.
- •Ongoing participation to another clinical investigational study.
研究组 & 干预措施
Reference therapy arm
Active Comparator
Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
干预措施: Anagrelide (Drug)
Reference therapy arm
Active Comparator
Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
干预措施: IFNα/ PegIFNα (Drug)
Investigational therapy arm
Experimental
Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.
Maximum dose 25 mg BID.
干预措施: Ruxolitinib (JAKAVI®) (Drug)
结局指标
主要结局
Failure-free patients
时间窗: month 12
Failure is defined by the occurrence of either intolerance and/or resistance to the second line therapy according to the protocol criteria
次要结局
- Thrombotic and hemorrhagic events(48 months)
- Quality of life questionnaire(48 months)
- Complete hematologic response(48 months)
- Median dose(48 months)
- AE/SAE(48 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic AdenocarcinomaPancreas, AdenocarcinomaNCT01413087Anchiano Therapeutics Israel Ltd.12
进行中（未招募）
2 期
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-DaraMultiple MyelomaNCT03896737European Myeloma Network B.V.401
Unknown
2 期
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical ResectionHepatocellular Carcinoma (HCC)NCT05213637Chinese PLA General Hospital430
招募中
2 期
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell LymphomaMantle Cell LymphomaNCT05245656Kim, Seok Jin90
招募中
2 期
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLACUTE LYMPHOBLASTIC LEUKEMIANCT05748171Pfizer100